Myeloid NGS Panel

Diagnostic Use

This Next Generation Sequencing (NGS) panel targets 54 of the most commonly mutated genes/hotspot regions associated with myeloid neoplasms, including: acute myeloid leukaemia (AML); myelodysplastic syndrome (MDS); myeloproliferative neoplasms (MPN); chronic myelogenous leukaemia (CML); chronic myelomonocytic leukaemia (CMML); and juvenile myelomonocytic leukaemia (JMML). This test can be utilised to aid diagnosis, prognostication, disease monitoring, therapeutic intervention and patient management in haematological malignancies.

The panel content was designed by a consortium of recognized experts in blood cancer disorders. Targeted genes include those involved in the MDS-AML continuum as cited by professional organizations including the National Comprehensive Cancer Network (NCCN) and the European Society for Medical Oncology (ESMO), providing a comprehensive picture of the disease and its progression.


Genetics - Molecular Oncology

Delphic Registration Code


Laboratory Handling


2x EDTA (Lavender) dedicated to Genetics (same sample can be used for FLT3/NPM1/CEBPA testing)


Send to MONC

Turnaround Time

21 days

Test Code